Kabi Decries ‘Broken Record’ Query As US Tocilizumab Wait Continues
German Firm Received Setback Earlier This Year; First Mover In Europe
Executive Summary
Fresenius Kabi continues to feel confident “that we’re going to be pretty much first to market” for its Tyenne proposed biosimilar to Actemra in the US.